Physician profile
Danielle Buser
NPI 1659199461
$2,683.41
in general payments reported to CMS, 2019-2025
19 companies · $2,333 in 2025
The $2,333 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $350 · 2025: $2,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,514 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,513.78 |
| Education | $169.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $523.18 | 2024-2025 | |
| Janssen Biotech, INC. | $377.46 | 2024-2025 | Tremfya |
| Leo Pharma INC. | $351.70 | 2024-2025 | Adbry, Anzupgo, Spevigo |
| Regeneron Healthcare Solutions, INC. | $335.69 | 2024-2025 | Dupixent, Libtayo |
| Amgen INC. | $201.90 | 2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $153.49 | 2025 | Nemluvio |
| Genzyme Corporation | $152.55 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $101.34 | 2025 | |
| Lilly USA, LLC | $99.07 | 2025 | Ebglyss |
| Mallinckrodt Hospital Products INC. | $70.94 | 2025 | Acthar |
| Organon LLC | $68.14 | 2025 | Vtama |
| Pfizer INC. | $60.95 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.06 | 2025 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $30.24 | 2025 | Sotyktu |
| Ani Pharmaceuticals, INC. | $26.70 | 2025 | Purified Cortrophin Gel |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $24.34 | 2025 | |
| Botanix Sb INC | $16.82 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $15.67 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Buser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.